These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 24101549)
21. STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Escobar T; Yu CR; Muljo SA; Egwuagu CE Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4017-25. PubMed ID: 23674757 [TBL] [Abstract][Full Text] [Related]
22. STAT3 deficiency in B cells exacerbates uveitis by promoting expansion of pathogenic lymphocytes and suppressing regulatory B cells (Bregs) and Tregs. Oladipupo FO; Yu CR; Olumuyide E; Jittaysothorn Y; Choi JK; Egwuagu CE Sci Rep; 2020 Oct; 10(1):16188. PubMed ID: 33004854 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. Yu CR; Lee YS; Mahdi RM; Surendran N; Egwuagu CE PLoS One; 2012; 7(1):e29742. PubMed ID: 22238646 [TBL] [Abstract][Full Text] [Related]
24. Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation. Yu CR; Mahdi RR; Oh HM; Amadi-Obi A; Levy-Clarke G; Burton J; Eseonu A; Lee Y; Chan CC; Egwuagu CE Invest Ophthalmol Vis Sci; 2011 Sep; 52(9):6978-86. PubMed ID: 21778271 [TBL] [Abstract][Full Text] [Related]
25. Induction of antigen-specific Treg cells in treating autoimmune uveitis via bystander suppressive pathways without compromising anti-tumor immunity. Chen Z; Zhang T; Kam HT; Qiao D; Jin W; Zhong Y; Zhou M; Zhou H; Chong WP; Chen W; Chen J EBioMedicine; 2021 Aug; 70():103496. PubMed ID: 34280776 [TBL] [Abstract][Full Text] [Related]
26. [Effects of leflunomide on experimental autoimmune uveitis in Lewis rats]. Fang C; Zhou D; Zhan S; He Y; Lin Z; Huang C; Li J Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):754-61. PubMed ID: 26693771 [TBL] [Abstract][Full Text] [Related]
27. Acquisition of T regulatory function in cathepsin L-inhibited T cells by eye-derived CTLA-2alpha during inflammatory conditions. Sugita S; Horie S; Nakamura O; Maruyama K; Takase H; Usui Y; Takeuchi M; Ishidoh K; Koike M; Uchiyama Y; Peters C; Yamamoto Y; Mochizuki M J Immunol; 2009 Oct; 183(8):5013-22. PubMed ID: 19801522 [TBL] [Abstract][Full Text] [Related]
28. 4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells. Kim YH; Choi BK; Shin SM; Kim CH; Oh HS; Park SH; Lee DG; Lee MJ; Kim KH; Vinay DS; Kwon BS J Immunol; 2011 Aug; 187(3):1120-8. PubMed ID: 21715692 [TBL] [Abstract][Full Text] [Related]
29. TGF-beta promotes Th17 cell development through inhibition of SOCS3. Qin H; Wang L; Feng T; Elson CO; Niyongere SA; Lee SJ; Reynolds SL; Weaver CT; Roarty K; Serra R; Benveniste EN; Cong Y J Immunol; 2009 Jul; 183(1):97-105. PubMed ID: 19535626 [TBL] [Abstract][Full Text] [Related]
30. [Expression of suppressor of cytokine signaling in retina of experimental autoimmune uveoretinitis]. Wang H; Zhou ZC; Peng XY; Zhao M Zhonghua Yan Ke Za Zhi; 2008 Oct; 44(10):876-82. PubMed ID: 19176113 [TBL] [Abstract][Full Text] [Related]
31. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Bing SJ; Lyu C; Xu B; Wandu WS; Hinshaw SJ; Furumoto Y; Caspi RR; Gadina M; Gery I Mol Vis; 2020; 26():641-651. PubMed ID: 33088168 [TBL] [Abstract][Full Text] [Related]
32. Dual Function of the IRF8 Transcription Factor in Autoimmune Uveitis: Loss of IRF8 in T Cells Exacerbates Uveitis, Whereas Irf8 Deletion in the Retina Confers Protection. Kim SH; Burton J; Yu CR; Sun L; He C; Wang H; Morse HC; Egwuagu CE J Immunol; 2015 Aug; 195(4):1480-8. PubMed ID: 26163590 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542 [TBL] [Abstract][Full Text] [Related]
34. Suppressor of cytokine signaling 1 (SOCS1) mitigates anterior uveitis and confers protection against ocular HSV-1 infection. Yu CR; Hayashi K; Lee YS; Mahdi RM; Shen DF; Chan CC; Egwuagu CE Inflammation; 2015 Apr; 38(2):555-65. PubMed ID: 24993154 [TBL] [Abstract][Full Text] [Related]
35. Deletion of Kang M; Lee HS; Choi JK; Yu CR; Egwuagu CE Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803441 [TBL] [Abstract][Full Text] [Related]
36. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. Luger D; Silver PB; Tang J; Cua D; Chen Z; Iwakura Y; Bowman EP; Sgambellone NM; Chan CC; Caspi RR J Exp Med; 2008 Apr; 205(4):799-810. PubMed ID: 18391061 [TBL] [Abstract][Full Text] [Related]
37. Pathogenic Function of Herpesvirus Entry Mediator in Experimental Autoimmune Uveitis by Induction of Th1- and Th17-Type T Cell Responses. Sakoda Y; Nagai T; Murata S; Mizuno Y; Kurosawa H; Shoda H; Morishige N; Yanai R; Sonoda KH; Tamada K J Immunol; 2016 Apr; 196(7):2947-54. PubMed ID: 26912321 [TBL] [Abstract][Full Text] [Related]
38. Interleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis. Kang M; Choi JK; Jittayasothorn Y; Egwuagu CE Front Immunol; 2020; 11():1051. PubMed ID: 32547555 [TBL] [Abstract][Full Text] [Related]
39. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. Grajewski RS; Hansen AM; Agarwal RK; Kronenberg M; Sidobre S; Su SB; Silver PB; Tsuji M; Franck RW; Lawton AP; Chan CC; Caspi RR J Immunol; 2008 Oct; 181(7):4791-7. PubMed ID: 18802082 [TBL] [Abstract][Full Text] [Related]
40. STAT3-Specific Single Domain Nanobody Inhibits Expansion of Pathogenic Th17 Responses and Suppresses Uveitis in Mice. Mbanefo EC; Yan M; Kang M; Alhakeem SA; Jittayasothorn Y; Yu CR; Parihar A; Singh S; Egwuagu CE Front Immunol; 2021; 12():724609. PubMed ID: 34603297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]